Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Sanofi SA — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5, while Sanofi SA trades at $43.25 (market cap $104.57B). The key difference: Sanofi SA pays a 5.56% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none, and State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| BIL | SNY | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $52.34 |
52-Week Low | $91.27 | $41.33 |
Market Cap | — | $104.57B |
Enterprise Value | — | $124.48B |
Dividend Yield | — | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.
As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.
SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.
SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
